GLP-1s and Birth Control in Perimenopause: What Actually Changes

GLP-1 medications work partly by slowing gastric emptying, the rate at which food and, importantly, oral medications move from the stomach into the small intestine where most absorption happens. This is a core part of how these drugs reduce appetite and slow the blood sugar spike after eating, but it also means anything else swallowed around the same time, including a daily birth control pill, may be absorbed more slowly or less completely.

This effect is documented specifically for oral semaglutide (Rybelsus) in its FDA prescribing information, which states that Rybelsus can reduce the extent of absorption of oral contraceptives. This is different from injectable GLP-1s, which deliver the medication directly into the bloodstream rather than through the gut, though the general slowing of digestion still applies to some degree with any GLP-1.

The concern isn't theoretical: even a modest reduction in how much of a birth control pill's hormone reaches circulation can be enough to reduce its contraceptive reliability, particularly for lower-dose combination pills or progestin-only pills that already have a narrower margin for missed or reduced doses.

The Rybelsus prescribing information advises that women using oral hormonal contraceptives switch to a non-oral contraceptive method, or add a barrier method such as condoms, for 4 weeks after starting Rybelsus and for 4 weeks after any dose increase. This 4-week window reflects the period when the drug's effect on gastric emptying is being newly established or intensified at each step.

This guidance doesn't apply the same way to injectable GLP-1s like Ozempic, Wegovy, Mounjaro, or Zepbound, which don't carry this specific interaction warning in their labels. That said, all GLP-1s can cause nausea, vomiting, and diarrhea, especially during dose increases, and vomiting within a few hours of taking any pill, including a birth control pill, can reduce how much of it is actually absorbed regardless of the GLP-1 interaction question.

The practical takeaway is to treat any GLP-1 dose increase, oral or injectable, as a moment to double-check contraceptive reliability if avoiding pregnancy is a priority, rather than assuming only Rybelsus users need to think about this.

Yes, and often in a direction people don't expect. Many women assume that irregular periods in perimenopause mean reduced fertility or a low chance of pregnancy, but ovulation can still occur unpredictably during this transition, sometimes even after several skipped cycles. Perimenopause is only confirmed to have ended, and true menopause begun, after 12 consecutive months without a period.

This means someone in perimenopause who is also starting or adjusting a GLP-1 is navigating two sources of unpredictability at once: hormonal cycle irregularity from perimenopause itself, and a potential absorption interaction from an oral GLP-1. Neither one cancels the other out, and assuming pregnancy risk is automatically lower because of age or irregular cycles is a common and understandable mistake.

For more on how perimenopause cycles change generally, see [irregular periods in perimenopause](/blog/irregular-periods-in-perimenopause-whats-normal) and [birth control in perimenopause](/blog/birth-control-in-perimenopause-what-to-use-after-40).

For anyone who wants to sidestep the absorption question entirely, non-oral methods remove the variable altogether. A hormonal or copper IUD, a contraceptive implant, or a contraceptive patch don't rely on the digestive system for absorption, making them a straightforward choice for someone on any GLP-1, oral or injectable.

If staying on an oral contraceptive pill is preferred, the FDA-recommended approach for Rybelsus users, adding a barrier method for the first 4 weeks after starting or increasing the dose, is a reasonable middle ground. For injectable GLP-1 users without this specific label warning, the main practical advice is to be attentive during periods of significant nausea or vomiting, when any oral medication's absorption may be compromised.

This is ultimately a conversation to have directly with a prescriber or gynecologist, since the right choice depends on which GLP-1 you're taking, your current contraceptive method, and how important avoiding pregnancy is to you at this point in perimenopause.

This is a related but separate question from contraceptive absorption. Significant weight loss, which GLP-1s often produce, can actually increase fertility in some women, particularly those with conditions like PCOS where excess weight was suppressing regular ovulation. This means someone who assumed pregnancy was unlikely due to weight or irregular cycles may find their fertility improving as they lose weight on a GLP-1, on top of the perimenopause unpredictability already discussed.

This is a well-documented pattern in women of reproductive age with PCOS starting GLP-1 therapy, and while less studied specifically in perimenopause, the same basic mechanism, improved insulin sensitivity and hormonal regulation with weight loss, could plausibly apply. For more detail on stopping a GLP-1 around a planned pregnancy, see [GLP-1 and fertility: when to stop before pregnancy](/blog/glp1-and-fertility-when-to-stop-before-pregnancy).

The combined effect of improving fertility from weight loss, unpredictable perimenopausal ovulation, and a possible absorption interaction with oral contraceptives makes this a genuinely nuanced situation worth a dedicated conversation with your doctor, not a set-and-forget assumption.

Every combination of GLP-1 medication, contraceptive method, and stage of perimenopause is a little different. If you want help thinking through what applies to your specific situation before your next appointment, [ask Lea](https://meetlea.ai/chat?q=Does+my+GLP-1+medication+affect+my+birth+control+during+perimenopause%3F) to help you prepare the right questions.